{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:03:31Z","timestamp":1792494211639,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"Ministry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-024-00755-y","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T12:12:46Z","timestamp":1732104766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pediatric brain tumor patients display altered immune activation and reduced lymphopoiesis at the onset of disease"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-414X","authenticated-orcid":false,"given":"Marco","family":"Rosichini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Del Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Dolores","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2900-6636","authenticated-orcid":false,"given":"Francesca","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Genah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Cerimele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Coccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Flamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Carsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cacchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mastronuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8383-0453","authenticated-orcid":false,"given":"Enrico","family":"Velardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1056\/NEJMra2116344","volume":"386","author":"AR Cohen","year":"2022","unstructured":"Cohen, A. R. Brain tumors in children. N. Engl. J. Med. 386, 1922\u20131931 (2022).","journal-title":"N. Engl. J. Med."},{"key":"755_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.08.004","volume":"104","author":"F Malbari","year":"2020","unstructured":"Malbari, F. & Lindsay, H. Genetics of common pediatric brain tumors. Pediatr. Neurol. 104, 3\u201312 (2020).","journal-title":"Pediatr. Neurol."},{"key":"755_CR3","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/brainsci13071106","volume":"13","author":"S Damodharan","year":"2023","unstructured":"Damodharan, S. & Puccetti, D. Pediatric central nervous system tumor overview and emerging treatment considerations. Brain Sci. 13, 1106 (2023).","journal-title":"Brain Sci."},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1158\/1055-9965.EPI-14-0207","volume":"23","author":"KJ Johnson","year":"2014","unstructured":"Johnson, K. J. et al. Childhood brain tumor epidemiology: A brain tumor epidemiology consortium review. Cancer Epidemiol. Biomark. Prev. 23, 2716\u20132736 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"755_CR5","doi-asserted-by":"crossref","unstructured":"Kalluri, A. L., Shah, P. P. & Lim, M. The Tumor Immune microenvironment in primary CNS neoplasms: a review of current knowledge and therapeutic approaches. Int. J. Mol. Sci. 24, 2020 (2023).","DOI":"10.3390\/ijms24032020"},{"key":"755_CR6","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.3390\/cancers15143655","volume":"15","author":"S Budhiraja","year":"2023","unstructured":"Budhiraja, S. et al. Immunobiology and Cytokine modulation of the pediatric brain tumor microenvironment: a scoping review. Cancers 15, 3655 (2023).","journal-title":"Cancers"},{"key":"755_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","volume":"151","author":"MM Grabowski","year":"2021","unstructured":"Grabowski, M. M. et al. Immune suppression in gliomas. J. Neurooncol, 151, 3\u201312 (2021).","journal-title":"J. Neurooncol,"},{"key":"755_CR8","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.4049\/jimmunol.171.9.4927","volume":"171","author":"CJ Wheeler","year":"2003","unstructured":"Wheeler, C. J. et al. Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J. Immunol. 171, 4927\u20134933 (2003).","journal-title":"J. Immunol."},{"key":"755_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1036211","volume":"4","author":"O Fornara","year":"2015","unstructured":"Fornara, O. et al. Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery. Oncoimmunology 4, 1\u201314 (2015).","journal-title":"Oncoimmunology"},{"key":"755_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11060-017-2678-3","volume":"136","author":"S Patel","year":"2018","unstructured":"Patel, S., Wang, S., Snuderl, M. & Karajannis, M. A. Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma. J. Neurooncol. 136, 541\u2013544 (2018).","journal-title":"J. Neurooncol."},{"key":"755_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.00327","volume":"9","author":"M Yalon","year":"2019","unstructured":"Yalon, M. et al. Elevated NLR may be a feature of pediatric brain cancer patients. Front Oncol. 9, 1\u20135 (2019).","journal-title":"Front Oncol."},{"key":"755_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2302892","volume":"389","author":"KA Kooshesh","year":"2023","unstructured":"Kooshesh, K. A., Foy, B. H., Sykes, D. B., Gustafsson, K. & Scadden, D. T. Health consequences of thymus removal in adults. N. Engl. J. Med. 389, 406\u2013417 (2023).","journal-title":"N. Engl. J. Med."},{"key":"755_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41577-020-00457-z","volume":"21","author":"E Velardi","year":"2021","unstructured":"Velardi, E., Tsai, J. J. & van den Brink, M. R. M. T cell regeneration after immunological injury. Nat. Rev. Immunol. 21, 277\u2013291 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"755_CR14","doi-asserted-by":"crossref","unstructured":"Aran, A., Garrig\u00f3s, L., Curigliano, G., Cort\u00e9s, J. & Mart\u00ed, M. Evaluation of the TCR Repertoire as a predictive and prognostic biomarker in cancer: diversity or clonality? Cancers. 14, 1771 (2022).","DOI":"10.3390\/cancers14071771"},{"key":"755_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.752042","volume":"12","author":"A Cardinale","year":"2021","unstructured":"Cardinale, A., De Luca, C. D., Locatelli, F. & Velardi, E. Thymic function and T-cell receptor repertoire diversity: implications for patient response to checkpoint blockade immunotherapy. Front Immunol. 12, 1\u201312 (2021).","journal-title":"Front Immunol."},{"key":"755_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet, P. et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 24, 1459\u20131468 (2018).","journal-title":"Nat. Med."},{"key":"755_CR17","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1093\/brain\/awaa343","volume":"143","author":"K Ayasoufi","year":"2020","unstructured":"Ayasoufi, K. et al. Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators. Brain 143, 3629\u20133652 (2020).","journal-title":"Brain"},{"key":"755_CR18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"755_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/neuonc\/noq001","volume":"12","author":"MP Gustafson","year":"2010","unstructured":"Gustafson, M. P. et al. Systemic immune suppression in glioblastoma: The interplay between CD14 +HLA-DR lo\/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 12, 631\u2013644 (2010).","journal-title":"Neuro Oncol."},{"key":"755_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1326757","volume":"15","author":"AA Stepanenko","year":"2024","unstructured":"Stepanenko, A. A. et al. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy. Front. Immunol. 15, 1326757 (2024).","journal-title":"Front. Immunol."},{"key":"755_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","volume":"84","author":"F Bigot","year":"2017","unstructured":"Bigot, F. et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur. J. Cancer 84, 212\u2013218 (2017).","journal-title":"Eur. J. Cancer"},{"key":"755_CR22","doi-asserted-by":"crossref","unstructured":"Murphy, K. A. & Griffith, T. S. CD8 T Cell-independent antitumor response and its potential for treatment of malignant gliomas. Cancers. 8, 22 (2016).","DOI":"10.3390\/cancers8080071"},{"key":"755_CR23","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1182\/blood-2004-04-1667","volume":"105","author":"E Clave","year":"2005","unstructured":"Clave, E. et al. Prognostic value of pretransplantation host thymic function in HLA-identical sibling hematopoietic stem cell transplantation. Blood 105, 2608\u20132613 (2005).","journal-title":"Blood"},{"key":"755_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaci.2023.01.022","volume":"151","author":"M Rosichini","year":"2023","unstructured":"Rosichini, M. et al. SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity. J. Allergy Clin. Immunol. 151, 911\u2013921 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"755_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cyto.b.21728","volume":"96","author":"M Garcia-Prat","year":"2019","unstructured":"Garcia-Prat, M. et al. Extended immunophenotyping reference values in a healthy pediatric population. Cytom. B Clin. Cytom. 96, 223\u2013233 (2019).","journal-title":"Cytom. B Clin. Cytom."},{"key":"755_CR26","unstructured":"Lanzkowsky, P., Lipton, J.M. & Fish, J.D. Lanzkowsky's Manual of Pediatric Hematology and Oncology (Sixth Edition). Academic Press, A1, 709\u2013728 (2016)."},{"key":"755_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/ijlh.14068","volume":"45","author":"MK Bohn","year":"2023","unstructured":"Bohn, M. K., Wilson, S., Steele, S. & Adeli, K. Comprehensive pediatric reference intervals for 79 hematology markers in the CALIPER cohort of healthy children and adolescents using the Mindray BC-6800Plus system. Int J. Lab Hematol. 45, 469\u2013480 (2023).","journal-title":"Int J. Lab Hematol."},{"key":"755_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-019-1549-2","volume":"19","author":"Z Huang","year":"2019","unstructured":"Huang, Z. et al. Eosinophils and other peripheral blood biomarkers in glioma grading: A preliminary study. BMC Neurol. 19, 1\u201311 (2019).","journal-title":"BMC Neurol."},{"key":"755_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel, A. M., Yang, C., Thakar, M. S. & Malarkannan, S. Natural killer cells: Development, maturation, and clinical utilization. Front Immunol. 9, 1\u201323 (2018).","journal-title":"Front Immunol."},{"key":"755_CR30","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1002\/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4","volume":"31","author":"R Jacobs","year":"2001","unstructured":"Jacobs, R. et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur. J. Immunol. 31, 3121\u20133127 (2001).","journal-title":"Eur. J. Immunol."},{"key":"755_CR31","doi-asserted-by":"publisher","first-page":"881427","DOI":"10.3389\/fimmu.2022.881427","volume":"13","author":"Y Qin","year":"2022","unstructured":"Qin, Y., Lu, F., Lyu, K., Chang, A. E. & Li, Q. Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity. Front Immunol. 13, 881427 (2022).","journal-title":"Front Immunol."},{"key":"755_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s001090100271","volume":"79","author":"MD Hazenberg","year":"2001","unstructured":"Hazenberg, M. D., Verschuren, M. C., Hamann, D., Miedema, F. & Dongen, J. J. T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J. Mol. Med 79, 631\u2013640 (2001).","journal-title":"J. Mol. Med"},{"key":"755_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3171\/2018.10.PEDS18377","volume":"23","author":"IF Pollack","year":"2019","unstructured":"Pollack, I. F., Agnihotri, S. & Broniscer, A. Childhood brain tumors: Current management, biological insights, and future directions. J. Neurosurg. Pediatr. 23, 261\u2013273 (2019).","journal-title":"J. Neurosurg. Pediatr."},{"key":"755_CR34","first-page":"1257","volume":"12","author":"T Stokland","year":"2010","unstructured":"Stokland, T. et al. A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol. 12, 1257\u20131268 (2010).","journal-title":"Neuro Oncol."},{"key":"755_CR35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ijrobp.2018.11.004","volume":"103","author":"JM Cherlow","year":"2019","unstructured":"Cherlow, J. M. et al. Conformal radiation therapy for pediatric patients with low-grade glioma: results from the children\u2019s Oncology Group Phase 2 Study ACNS0221. Int J. Radiat. Oncol. Biol. Phys. 103, 861\u2013868 (2019).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"755_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00412-015-0510-4","volume":"124","author":"S Kallappagoudar","year":"2015","unstructured":"Kallappagoudar, S., Yadav, R. K., Lowe, B. R. & Partridge, J. F. Histone H3 mutations\u2013a special role for H3.3 in tumorigenesis? Chromosoma 124, 177\u2013189 (2015).","journal-title":"Chromosoma"},{"key":"755_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12017-015-8362-x","volume":"17","author":"K Eder","year":"2015","unstructured":"Eder, K. & Kalman, B. The dynamics of interactions among immune and glioblastoma cells. Neuromol. Med 17, 335\u2013352 (2015).","journal-title":"Neuromol. Med"},{"key":"755_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2015.07.019","volume":"53","author":"P Domingues","year":"2016","unstructured":"Domingues, P. et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav. Immun. 53, 1\u201315 (2016).","journal-title":"Brain Behav. Immun."},{"key":"755_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1215\/15228517-2006-008","volume":"8","author":"SF Hussain","year":"2006","unstructured":"Hussain, S. F. et al. The role of human glioma-infiltrating microglia\/macrophages in mediating antitumor immune responses1. Neuro Oncol. 8, 261\u2013279 (2006).","journal-title":"Neuro Oncol."},{"key":"755_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bpa.12927","volume":"31","author":"M Gonz\u00e1lez\u2010Tablas Pimenta","year":"2021","unstructured":"Gonz\u00e1lez\u2010Tablas Pimenta, M. et al. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. Brain Pathol. 31, 365\u2013380 (2021).","journal-title":"Brain Pathol."},{"key":"755_CR41","doi-asserted-by":"crossref","unstructured":"Chen, J. et al. Immune cell analysis of pilocytic astrocytomas reveals sexually dimorphic brain region-specific differences in T-cell content. Neurooncol. Adv. 3, vdab068 (2021).","DOI":"10.1093\/noajnl\/vdab068"},{"key":"755_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson, J. H., Gunn, M. D., Fecci, P. E. & Ashley, D. M. Brain immunology and immunotherapy in brain tumours. Nat. Rev. Cancer 20, 12\u201325 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"755_CR43","doi-asserted-by":"publisher","first-page":"e001066","DOI":"10.1136\/jitc-2020-001066","volume":"8","author":"MH Robinson","year":"2020","unstructured":"Robinson, M. H. et al. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. J. Immunother. Cancer 8, e001066 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"755_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/neuonc\/noaa259","volume":"23","author":"K Mitchell","year":"2021","unstructured":"Mitchell, K., Troike, K., Silver, D. J. & Lathia, J. D. The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions. Neuro Oncol. 23, 199\u2013213 (2021).","journal-title":"Neuro Oncol."},{"key":"755_CR45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJK Guthrie","year":"2013","unstructured":"Guthrie, G. J. K. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 88, 218\u2013230 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"755_CR46","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI: J. Natl Cancer Inst. 106, dju124 (2014).","journal-title":"JNCI: J. Natl Cancer Inst."},{"key":"755_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.suronc.2013.12.001","volume":"23","author":"A Paramanathan","year":"2014","unstructured":"Paramanathan, A., Saxena, A. & Morris, D. L. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg. Oncol. 23, 31\u201339 (2014).","journal-title":"Surg. Oncol."},{"key":"755_CR48","doi-asserted-by":"publisher","first-page":"59217","DOI":"10.18632\/oncotarget.19484","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang, J. et al. Prognostic role of neutrophil lymphocyte ratio in patients with glioma. Oncotarget 8, 59217\u201359224 (2017).","journal-title":"Oncotarget"},{"key":"755_CR49","doi-asserted-by":"publisher","first-page":"e710","DOI":"10.1016\/j.wneu.2018.07.252","volume":"119","author":"Y Bao","year":"2018","unstructured":"Bao, Y. et al. Preoperative hematologic inflammatory markers as prognostic factors in patients with glioma. World Neurosurg. 119, e710\u2013e716 (2018).","journal-title":"World Neurosurg."},{"key":"755_CR50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/0022-3859.180551","volume":"62","author":"V Subeikshanan","year":"2016","unstructured":"Subeikshanan, V. et al. A prospective comparative clinical study of peripheral blood counts and indices in patients with primary brain tumors. J. Postgrad. Med 62, 86\u201390 (2016).","journal-title":"J. Postgrad. Med"},{"key":"755_CR51","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.2147\/OTT.S113606","volume":"9","author":"R Auezova","year":"2016","unstructured":"Auezova, R. et al. Association of preoperative levels of selected blood inflammatory markers with prognosis in gliomas. Onco Targets Ther. 9, 6111\u20136117 (2016).","journal-title":"Onco Targets Ther."},{"key":"755_CR52","doi-asserted-by":"publisher","first-page":"577754","DOI":"10.1016\/j.jneuroim.2021.577754","volume":"361","author":"ST Chim","year":"2021","unstructured":"Chim, S. T., Sanfilippo, P., O\u2019Brien, T. J., Drummond, K. J. & Monif, M. Pretreatment neutrophil-to-lymphocyte\/monocyte-to-lymphocyte ratio as prognostic biomarkers in glioma patients. J. Neuroimmunol. 361, 577754 (2021).","journal-title":"J. Neuroimmunol."},{"key":"755_CR53","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1055\/s-0039-3399489","volume":"10","author":"KG Ashwath","year":"2019","unstructured":"Ashwath, K. G., Aggarwal, A., Praneeth, K., Singla, N. & Gupta, K. Neutrophil-to-lymphocyte ratio: can it be used as an adjunct tool to predict histopathological grade of brain tumor? J. Neurosci. Rural Pr. 10, 648\u2013652 (2019).","journal-title":"J. Neurosci. Rural Pr."},{"key":"755_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103372","volume":"163","author":"A Gomes dos Santos","year":"2021","unstructured":"Gomes dos Santos, A. et al. Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review. Crit. Rev. Oncol. Hematol. 163, 103372 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"755_CR55","doi-asserted-by":"publisher","first-page":"e01681","DOI":"10.1016\/j.heliyon.2019.e01681","volume":"5","author":"R Kemerdere","year":"2019","unstructured":"Kemerdere, R., Akgun, M. Y., Toklu, S., Alizada, O. & Tanriverdi, T. Preoperative systemic inflammatory markers in low- and high-grade gliomas: A retrospective analysis of 171 patients. Heliyon 5, e01681 (2019).","journal-title":"Heliyon"},{"key":"755_CR56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.omto.2020.12.012","volume":"20","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Classification of pediatric gliomas based on immunological profiling: implications for immunotherapy strategies. Mol. Ther. Oncolyt. 20, 34\u201347 (2021).","journal-title":"Mol. Ther. Oncolyt."},{"key":"755_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40272-021-00482-y","volume":"24","author":"A Gupta","year":"2022","unstructured":"Gupta, A. & Cripe, T. P. Immunotherapies for pediatric solid tumors: a targeted update. Paediatr. Drugs 24, 1\u201312 (2022).","journal-title":"Paediatr. Drugs"},{"key":"755_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/2326-6066.CIR-19-0692","volume":"8","author":"DL Casey","year":"2020","unstructured":"Casey, D. L. & Cheung, N.-K. V. Immunotherapy of pediatric solid tumors: treatments at a crossroads, with an emphasis on antibodies. Cancer Immunol. Res. 8, 161\u2013166 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"755_CR59","doi-asserted-by":"crossref","unstructured":"Guha, P., Heatherton, K. R., O\u2019Connell, K. P., Alexander, I. S. & Katz, S. C. Assessing the future of solid tumor immunotherapy. Biomedicines 10, 655 (2022).","DOI":"10.3390\/biomedicines10030655"},{"key":"755_CR60","doi-asserted-by":"publisher","first-page":"961805","DOI":"10.3389\/fimmu.2022.961805","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu, C., Yang, M., Zhang, D., Chen, M. & Zhu, D. Clinical cancer immunotherapy: Current progress and prospects. Front Immunol. 13, 961805 (2022).","journal-title":"Front Immunol."},{"key":"755_CR61","doi-asserted-by":"crossref","unstructured":"Chen, X., Cui, Y. & Zou, L. Treatment advances in high-grade gliomas. Front. Oncol. 14, 1287725 (2024).","DOI":"10.3389\/fonc.2024.1287725"},{"key":"755_CR62","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3389\/fimmu.2018.00727","volume":"9","author":"C-I Jan","year":"2018","unstructured":"Jan, C.-I. et al. Predictors of response to autologous dendritic cell therapy in glioblastoma multiforme. Front Immunol. 9, 727 (2018).","journal-title":"Front Immunol."},{"key":"755_CR63","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00262-018-2232-y","volume":"67","author":"Y Yao","year":"2018","unstructured":"Yao, Y. et al. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol. Immunother. 67, 1777\u20131788 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"755_CR64","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1158\/1078-0432.CCR-16-1369","volume":"23","author":"O Bloch","year":"2017","unstructured":"Bloch, O. et al. Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 Expression on response to therapy. Clin. Cancer Res 23, 3575\u20133584 (2017).","journal-title":"Clin. Cancer Res"},{"key":"755_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.30220","volume":"70","author":"L Mayr","year":"2023","unstructured":"Mayr, L. et al. Viral infections in pediatric brain tumor patients treated with targeted therapies. Pediatr. Blood Cancer 70, 1\u20138 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"755_CR66","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","volume":"17","author":"SA Grossman","year":"2011","unstructured":"Grossman, S. A. et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin. Cancer Res. 17, 5473\u20135480 (2011).","journal-title":"Clin. Cancer Res."},{"key":"755_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06796-3","volume":"20","author":"Z Cai","year":"2020","unstructured":"Cai, Z., Yang, S., Li, X., Chen, F. & Li, W. Viral infection and glioma: a meta-analysis of prognosis. BMC Cancer 20, 549 (2020).","journal-title":"BMC Cancer"},{"key":"755_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100950","volume":"7","author":"C Terrones-Campos","year":"2022","unstructured":"Terrones-Campos, C. et al. Risk of bacterial, viral, and fungal infections in patients with solid malignant tumors treated with curative intent radiation therapy. Adv. Radiat. Oncol. 7, 100950 (2022).","journal-title":"Adv. Radiat. Oncol."},{"key":"755_CR69","doi-asserted-by":"crossref","unstructured":"Wang, Q. et al. Changes in T lymphocyte subsets in different tumors before and after radiotherapy: a meta-analysis. Front. Immunol. 12, 648652 (2021).","DOI":"10.3389\/fimmu.2021.648652"},{"key":"755_CR70","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","volume":"7","author":"C M\u00e9n\u00e9trier-Caux","year":"2019","unstructured":"M\u00e9n\u00e9trier-Caux, C., Ray-Coquard, I., Blay, J.-Y. & Caux, C. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with Cytokines? J. Immunother. Cancer 7, 85 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"755_CR71","doi-asserted-by":"crossref","unstructured":"C\u00e9z\u00e9, N. et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother. Pharmacol. 68, 1305\u201313 (2011).","DOI":"10.1007\/s00280-011-1610-3"},{"key":"755_CR72","doi-asserted-by":"crossref","unstructured":"Kou, F. et al. Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. Cancer Med. 5, 778\u201386 (2016).","DOI":"10.1002\/cam4.638"},{"key":"755_CR73","doi-asserted-by":"crossref","unstructured":"He, J. R. et al. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck 34, 1769\u201376 (2012).","DOI":"10.1002\/hed.22008"},{"key":"755_CR74","doi-asserted-by":"crossref","unstructured":"Che, Y. Q. et al. Baseline Lymphopenia: A predictor of poor outcomes In HER2 positive metastatic breast cancer treated with Trastuzumab. Drug Des. Dev. Ther. 13, 3727\u20133734 (2019).","DOI":"10.2147\/DDDT.S212610"},{"key":"755_CR75","doi-asserted-by":"crossref","unstructured":"Emile, G. et al. Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. Oncol. Lett. 23, 25 (2022).","DOI":"10.3892\/ol.2021.13143"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00755-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T13:11:14Z","timestamp":1732108274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00755-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1038\/s41698-024-00755-y","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest related to this work. Prof. Locatelli reports personal fees from Amgen, personal fees from Novartis, other from Bellicum Pharmaceutical, other from Neovii, personal fees from Miltenyi, personal fees from Medac, personal fees from Jazz Pharmaceutical, personal fees from Takeda, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}